Group items matching

in title, tags, annotations or url

Balmedie Pharmacy based in Aberdeenshire, Scotland has been purchased by local expanding multiple operator JMF Healthcare. Balmedie Pharmacy is a well-performing community pharmacy that dispenses an average of 5,255 items per month. It lies completely unopposed in the large Aberdeenshire village of Balmedie, which is circa eight miles north of Aberdeen City Centre. The pharmacy has been owned by Brian Arris since 2004 and was recently brought to market to allow him to pursue other pharmacy business opportunities. Following a confidential sales process with Christie & Co, JMF Healthcare to benefit from new housing developments in this area of Aberdeenshire such as 300 new homes planned in Balmedie, approved plans for up to 500 new homes in Trump Menie Estate, and 284 new homes planned in Blackdog Village. Brian Arris, previous owner of Balmedie Pharmacy, comments, "I'm sad to see the business go as the excellent staff have helped grow the pharmacy from scratch since 2004 and we've all put our hearts and souls into providing good pharmaceutical care for the village and surrounding area. I'm confident everyone is left in safe hands with John at the helm now."

Salrook Healthcare, a family-run pharmacies in Chester has sold its two well-established community pharmacies named Westminster Park Pharmacy on Castle Croft Road and Owen's Chemist on Chester Street. Together, they dispense circa 13,000 items per month. The business has been owned by the Persaud family since 2014 and was recently brought to the market as a retirement sale. Following a confidential process with Christie & Co, it has been purchased by Aqib Sheikh, an existing operator with a pharmacy in Walsall, West Midlands. Aqib plans to enhance the business's service offering and grow his portfolio in the region. Chloe Yadav (nee Persaud), previous owner of Salrook Healthcare Limited, comments, "As a family, we are delighted to have completed the sale of the business to Aqib. Whilst we will miss our team who have become like family, it is good to know that the two sites have been acquired by a forward- thinking Pharmacist who will enhance the offering to the benefit of the patients and the community which they serve. My family and I wish Aqib and the whole team the very best of luck with the future." Aqib Sheikh, new owner of Salrook Healthcare Limited, comments, "I am delighted to have inherited such a well-run and profitable pair of pharmacy businesses in the charming city of Chester. I'd like to wish John Persaud the very best with his retirement and look forward to building on the work of the Persaud family."

David Ogle and his family, who had been running the business for more than three decades, put it up for sale last year as they wanted to retire or pursue different business interests. Located in the Worcester city suburb of St Johns, DL Ogle Pharmacy dispenses an average of 12,000 items per month. The high-dispensing community pharmacy has been sold to brothers Ali and Mohammed Talib, Tapiwa Masamha and Chikondi Mlia, property adviser Christie & Co has revealed. The four brothers are also the owners of Gohil's Pharmacy and Whistlers Pharmacy in Lincolnshire. Carl Steer, Director - Pharmacy at Christie & Co. commented: "The sale was confidentially marketed but, within just a few days, interest was achieved from multiple parties, and we were able to present our client with an acceptable offer - this was a truly remarkable achievement but one that the long-standing business deserved.

British pharmacy chain Superdrug has announced plans to cease the sale of disposable vapes in all its UK and Ireland stores, citing the environmental impact caused by its disposal and popularity among young people. The pharmacy retailer will discontinue selling brands like Vuse GO and Flavaah Bars, with plans to completely clear out existing stock by the end of the year, the company said in statement. Superdrug, which previously sold 1,300 single-use vapes weekly, expects a potential impact on revenue stemming from this decision. The company has not yet started selling vapes online. "This decision was made to safeguard the environment," the company said on Sept.22, highlighting the risk of fires due to improper disposal of vapes, as many of them contain lithium batteries.

A man has been sentenced to three and a half years in prison for illegally importing and distributing unlicensed medicines from India, the Middle East, and the Far East. Antoine Christopher Kolias, 31, received his sentence at Southwark Crown Court on 28 June after being found guilty of criminal activities in May. The Medicines and Healthcare products Regulatory Agency's (MHRA) Criminal Enforcement Unit (CEU) led the investigation, dubbed Operation Bentley. Kolias was discovered to be acting both as a distributor for an established unlicensed medicines dealer and running his own illicit business. He was involved in the sale of sildenafil citrate, the active ingredient in Viagra, as well as Class C drugs including tramadol, zopiclone, and pregabalin between 2018 and 2019, and again between 2020 and 2021.

Superdrug, one of the leading health and beauty retailers, is all set to invest in 25 new stores this year, expanding its bricks-and-mortar retail footprint. It confirmed with Pharmacy Business that amongst its 25 new stores there "will be a mix of pharmacy and retail stores". The venture is expected to create over 570 jobs nationwide, creating a seamless customer experience and providing vital support for high streets and local communities. The investment, part of the brand's O+O (Online + Offline) platform strategy to deliver its omnichannel ambitions, is driven by continued strong performance figures. In Q4 2022 Superdrug reported increased volume and value sales and footfall across both sides of the beauty and health business. Whilst in 2021 revenue rose 5.1% to £1,168million with a profit before tax increase of 141.3%. The investment strategy has already seen Superdrug open new stores in Washington Gallery and Falkirk Retail Parks in February 2023 and in Braehead, the largest Superdrug in Scotland, just last month.

Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims. GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent. GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent listed company last month, comprises consumer health assets once partly owned by GSK. The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus. The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a note.

Covid-vaccine maker AstraZeneca said Friday that profits fell sharply in the first half on ballooning costs linked to its takeover of US biotech firm Alexion. The pharmaceutical group added that sales of its Covid-19 vaccine Vaxzevria slumped 49 percent in the second quarter. Net profit slumped 64 per cent to $746 million compared with the first six months of last year, AstraZeneca said in a statement. Operating expenses jumped 33 percent, "reflecting the addition of Alexion, and continued investment in new launches and the pipeline" of drugs, the group said. That offset a 48-percent jump in revenue to more than $22 billion. Revenue rose strongly thanks to sales of Alexion medicines. The group said annual revenue from Covid-19 medicines is anticipated to be broadly flat compared with 2021.

The Royal Pharmaceutical Society (RPS) has said that it strongly supports the UK government's proposal that individuals born on or after 1 January 2009 should be prohibited from legally purchasing tobacco products. It has also shown its agreement to several other actions proposed by the Department of Health and Social Care's (DHSC) for 'Creating a Smokefree Generation and Tackling Youth Vaping' including: The inclusion of all tobacco products, cigarette papers, and herbal smoking products in the new legislation. Restrictions on the sale and supply of disposable vapes, and vape flavours. RPS President, Professor Claire Anderson, said: "Our recommendations reflect a commitment to creating a future free from the harms of tobacco and youth vaping. It's crucial to prohibit access for the youngest generation, regulate all tobacco-related items, and address the allure of flavoured e-cigarettes."

The Department of Health and Social Care (DHSC) will introduce new arrangements for the setting of Drug Tariff Category A reimbursement prices from April 2024. Driven by ministers, DHSC's decision aims to equalise access to margin on Category A medicines and it's part of a series of drug reimbursement reforms proposed by the department following a public consultation in 2019. Currently, prices of medicines in Category A are subject to monthly adjustment. From 1 April 2024, these will be updated quarterly based on sales and volume data obtained by DHSC under the Health Service Products (Provision and Disclosure of Information) Regulations 2018. The transition will conclude in July 2025 when the reimbursement prices will be exclusively determined by the new method. Advance notice for contractors regarding the 'new arrangements' has been outlined on the NHSBSA website. However, Community Pharmacy England (CPE) did not support the introduction of the changes at this time as pharmacies are currently grappling with "wider challenges" and there is uncertainty about the potential impact of these changes on the already "turbulent" medicines supply chain

Buy Cheap Tramadol Online for sale with Cash on Delivery from the reputed pharmacy. Tramadol for sale, no prescription for buy Tramadol online with overnight shipping. Buy Tramadol Online now Contact Info Address: New York, NY Ph: (+1) 3473055444 Email : onlinecarehelpline@gmail.com website - https://www.youronlinerx.com

A new report from Archie Market Research says retail cannabis sales will jump 33% over 2016's totals to hit $10 billion this year. That's a faster pace than the group had previously predicted. Researchers say next year's numbers could increase by an even greater percentage.

Britain's biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies in the device and increase its ability to diagnose the Omicron variant. The company stated that AffiDX is capable of detecting Omicron when the virus is present in high numbers in samples, but the sensitivity of the test reduces at lower viral loads. The performance of all rapid antigen tests came under scanner in wake of a large number of mutations in the Omicron variant. AffiDX contains both a proprietary Affimer reagent and a commercially available antibody. The Affimer reagent detects the Omicron variant with the same sensitivity as the Delta variant, and performance of the antibody is paired with the Affimer reagent in the test. This has been affected by the additional Omicron mutations, the firm said. Alastair Smith, chief executive of Avacta Group, said: "Our determination to only provide high quality, high performance diagnostic tests has led us to the correct decision to pause all marketing of the AffiDX® lateral flow antigen test. We have, of course, been unable to market the product in the UK since October 2021, as the product continues to await approval under the new CTDA regulatory process.

Viveca Biomed has launched an innovative and clinically-proven bladder support device that offers women immediate relief from stress urinary incontinence (SUI) and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins. The product, named 'Contrelle Activgard', has already recorded millions of sales in Scandinavia over a decade. The company behind the UK launch is female healthcare business Viveca Biomed, founded in 2019 by Andrew Tasker who has spent 30+ years in senior roles within the OTC and pharma industry. Contrelle is manufactured, packed and distributed in the UK at Viveca Biomed's factory near Newcastle, with no outsourcing, and thus offering the best possible continuity of supply. Ahead of the launch, the company commissioned a large consumer lifestyle survey with 500 women over 40 years of age who experience bladder leaks, to reveal the extent of its detrimental impact. Contrelle Activgard is a safe, discrete, easy-to-use and highly effective, single-use vaginal device, designed to immediately prevent SUI rather than just deal with the leakage.

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

Kent based N.B. Pharmacy has been sold to first-time buyers, Venkat and Preeti Adama, from Essex for an undisclosed price. N.B. Pharmacy is a standard hours community pharmacy that dispenses an average of 6,393 items per month. The business has been owned by Nirmal Bajaria for 39 years and was recently brought to market to allow him to pursue a well-earned retirement. Following a confidential sales process with Christie & Co, it has been purchased by first-time buyers, Venkat and Preeti Adama, from Essex. Nirmal Bajaria, former owner of N.B. Pharmacy, comments, "Having run the pharmacy for around 39 years, it was a difficult decision to put the business up for sale. I was very pleased with the high number of viewers and feel delighted that a young family bought my pharmacy."

Boehringer Ingelheim UK & Ireland has appointed Vani Manja as its new Country Managing Director and Head of Human Pharma. Manja has been associated with Boehringer Ingelheim for over 11 years, in successful leadership roles in Germany, the United States and most recently as General Manager, India. Her career started as a commissioned officer in the Indian Army Ordnance Corps which preceded leadership roles at Becton Dickinson and McKinsey. She brings extensive experience of strategy, marketing, sales, business development, people management, and cultural transformation and is passionate about tackling healthcare inequalities and advancing sustainable healthcare. Commenting on her new role, Manja said: "It is with great heart that I bring the spirit of conscious leadership to my new role. I look forward to being fully present and partnering with key stakeholders in the healthcare ecosystem in our collective quest to improve health for humans and animals in the UK and Ireland."

Panadol launched a new purpose-led brand idea as part of a multi-channel campaign across Great Britain and Ireland. With nine out of 10 people suffering "everyday pain" and 65% of people saying they can't be happy when they are in pain[1], globally, the campaign reiterates the brand's commitment to holistic pain management by focusing on the acute pain recovery journey. Rooted in deep consumer understanding, the campaign idea celebrates that never-talked-about moment of realisation when you start to feel the release from pain. The new brand idea will bring to life the emotional transformation that those suffering from acute pain undergo, emphasising the role that Panadol can play in alleviating their pain. The Panadol campaign follows a period of strong sales growth for the brand, outperforming the category's own expansion by more than double[2]. This has been driven by shoppers who are searching for fast and effective pain relief products, such as Panadol's hero variants, including Panadol Extra Advance Tablets (paracetamol, caffeine), which has seen its growth almost doubled[3], as well as Panadol Advance Tablets (paracetamol) and Panadol Extra Advance Tablets. Monica Michalopoulou, GBI Marketing Director, said: "After two years of pandemic restrictions, now more than ever, people want to get back to their normal lives and to the people they love. But with pain preventing many of us from connecting with those we love or from doing the things we enjoy the most, we want to help consumers by understanding their pain journey and reassuring them on the treatments we can provide. This "Release" moment is so important for pain sufferers, and we hope our new brand campaign can shine a light on the role that Panadol can play in pain relief".

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

The Department of Health and Social Care (DHSC) has introduced a new 'swap to stop' scheme to encourage one million smokers to swap cigarettes for vapes in England. As part of the world-first national scheme, almost 1 in 5 of all smokers in England will be provided with a vape starter kit alongside behavioural support to help them quit the habit as part of a series of new measures to help the government meet its ambition of being smokefree by 2030 - reducing smoking rates to 5% or less. Local authorities will also be invited to take part in the scheme later this year and each will design a scheme which suits its needs, including deciding which populations to prioritise. Health Minister Neil O'Brien announced on Tuesday (11 April) that pregnant women will be offered financial incentives to help them stop smoking. This will involve offering vouchers, alongside behavioural support, to all pregnant women who smoke by the end of next year. The government will also consult on introducing mandatory cigarette pack inserts with positive messages and information to help people to quit smoking. It has also announced a formation of new 'illicit vapes enforcement squad' to regulate and tackle the sales of illegal vapes to under 18s.